290
Views
20
CrossRef citations to date
0
Altmetric
Original Articles

Age of initiation, psychopathology, and other substance use are associated with time to use disorder diagnosis in persons using opioids nonmedically

, PhD & , PhD

References

  • Nelson LS, Juurlink DN, Perrone J. Addressing the opioid epidemic. JAMA. 2015;314:1453–1454.
  • Substance Abuse and Mental Health Services Administration. Results From the 2013 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-48. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. HHS Publication No. (SMA) 14–4863.
  • Center for Behavioral Health Statistics and Quality. Behavioral Health Trends in the United States: Results From the 2014 National Survey on Drug Use and Health. NSDUH Series H-50. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015. HHS Publication No. SMA 15–4927.
  • Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD. Economic costs of nonmedical use of prescription opioids. Clin J Pain. 2011;27:194–202.
  • Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12:657–667.
  • Kerridge BT, Saha TD, Chou SP, et al. Gender and nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Drug Alcohol Depend. 2015;156:47–56.
  • Wang KH, Becker WC, Fiellin DA. Prevalence and correlates for nonmedical use of prescription opioids among urban and rural residents. Drug Alcohol Depend. 2013;127:156–162.
  • Han B, Compton WM, Jones CM, Cai R. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003–2013. JAMA. 2015;314:1468–1478.
  • Martins SS, Santaella-Tenorio J, Marshall BD, Maldonado A, Cerda M. Racial/ethnic differences in trends in heroin use and heroin-related risk behaviors among nonmedical prescription opioid users. Drug Alcohol Depend. 2015;151:278–283.
  • Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374:154–163.
  • Oderda GM, Lake J, Rudell K, Roland CL, Masters ET. Economic burden of prescription opioid misuse and abuse: a systematic review. J Pain Palliat Care Pharmacother. 2015;29:388–400.
  • Salas J, Scherrer JF, Lustman PJ, Schneider FD. Racial differences in the association between non-medical prescription opioid use, abuse/dependence and major depression. Subst Abus. 2016;37:25–50.
  • Cochran BN, Flentje A, Heck NC, et al. Factors predicting development of opioid use disorders among individuals who receive an initial opioid prescription: mathematical modeling using a database of commercially-insured individuals. Drug Alcohol Depend. 2014;138:202–208.
  • Katz C, El-Gabalawy R, Keyes KM, Martins SS, Sareen J. Risk factors for incident nonmedical prescription opioid use and abuse and dependence: results from a longitudinal nationally representative sample. Drug Alcohol Depend. 2013;132:107–113.
  • Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008;94:38–47.
  • Lawson KM, Back SE, Hartwell KJ, Moran-Santa Maria M, Brady KT. A comparison of trauma profiles among individuals with prescription opioid, nicotine, or cocaine dependence. Am J Addict. 2013;22:127–131.
  • McCabe SE, West BT, Morales M, Cranford JA, Boyd CJ. Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study. Addiction. 2007;102:1920–1930.
  • Huang B, Dawson DA, Stinson FS, et al. Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: results of the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67:1062–1073.
  • Saha TD, Kerridge BT, Goldstein RB, et al. Nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder in the United States. J Clin Psychiatry. 2016;77:772–780.
  • Parker MA, Anthony JC. Epidemiological evidence on extra-medical use of prescription pain relievers: transitions from newly incident use to dependence among 12–21 year olds in the United States using meta-analysis, 2002–13. PeerJ. 2015;3:e1340.
  • Grant BF, Kaplan KD. Source and Accuracy Statement for the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 2005.
  • Grant BF, Kaplan K, Shepard J, Moore T. Source and Accuracy Statement for Wave 1 of the 2001–2002 National Epidemiologic Survey on Alcohol and Related Conditions. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2003.
  • Boyd CJ, McCabe SE. Coming to terms with the nonmedical use of prescription medications. Subst Abuse Treat Prev Policy. 2008;3:22.
  • Boyd CJ, Teter CJ, West BT, Morales M, McCabe SE. Non-medical use of prescription analgesics: a three-year national longitudinal study. J Addict Dis. 2009;28:232–242.
  • Grant BF, Dawson DA, Stinson FS, Chou PS, Kay W, Pickering R. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. Drug Alcohol Depend. 2003;71:7–16.
  • Grant BF, Harford TC, Dawson DA, Chou PS, Pickering RP. The Alcohol Use Disorder And Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. Drug Alcohol Depend. 1995;39:37–44.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text rev. Washington, DC: American Psychiatric Association; 2000.
  • Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Regression. New York: Springer; 2005.
  • Bolland KA, Bolland JM, Tomek S, Devereaux RS, Mrug S, Wimberly JC. Trajectories of adolescent alcohol use by gender and early initiation status. Youth Soc. 2013;xx:xx–xx.
  • DeWit DJ, Adlaf EM, Offord DR, Ogborne AC. Age at first alcohol use: a risk factor for the development of alcohol disorders. Am J Psychiatry. 2000;157:745–750.
  • Hingson RW, Heeren T, Winter MR. Age at drinking onset and alcohol dependence: age at onset, duration, and severity. Arch Pediatr Adolesc Med. 2006;160:739–746.
  • Stueve A, O'Donnell LN. Early alcohol initiation and subsequent sexual and alcohol risk behaviors among urban youths. Am J Public Health. 2005;95:887–893.
  • Lynskey MT, Heath AC, Bucholz KK, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. 2003;289:427–433.
  • Sagar KA, Dahlgren MK, Gönenç A, Racine MT, Dreman MW, Gruber SA. The impact of initiation: early onset marijuana smokers demonstrate altered Stroop performance and brain activation. Dev Cogn Neurosci. 2015;16:84–92.
  • Horwood LJ, Fergusson DM, Hayatbakhsh MR, et al. Cannabis use and educational achievement: findings from three Australasian cohort studies. Drug Alcohol Depend. 2010;110:247–253.
  • Ellickson PL, Tucker JS, Klein DJ, Saner H. Antecedents and outcomes of marijuana use initiation during adolescence. Prev Med. 2004;39:976–984.
  • Cerdá M, Santaella J, Marshall BDL, Kim JH, Martins SS. Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: a national study. J Pediatr. 2015;167:605–612.e602.
  • Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: a natural history study. Drug Alcohol Depend. 2016;160:127–134.
  • Alvanzo AA, Storr CL, La Flair L, Green KM, Wagner FA, Crum RM. Race/ethnicity and sex differences in progression from drinking initiation to the development of alcohol dependence. Drug Alcohol Depend. 2011;118:375–382.
  • Khan SS, Secades-Villa R, Okuda M, et al. Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions. Drug Alcohol Depend. 2013;130:101–108.
  • Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. Psychiatr Clin North Am. 2010;33:339–355.
  • Stoltman JJ, Woodcock EA, Lister JJ, Greenwald MK, Lundahl LH. Exploration of the telescoping effect among not-in-treatment, intensive heroin-using research volunteers. Drug Alcohol Depend. 2015;148:217–220.
  • Hughes A, Williams MR, Lipari RN, Bose J, Copello EAP, Kroutil LA. Prescription drug use and misuse in the United States: results from the 2015 National Survey on Drug Use and Health. NSDUH Data Review. https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm. Published 2016. Accessed November 18, 2016.
  • Substance Abuse and Mental Health Services Administration. Reliability of Key Measures in the National Survey on Drug Use and Health. Office of Applied Studies, Methodology Series M-8. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2010. HHS Publication No. SMA 09–4425.
  • Cochran G, Woo B, Lo-Ciganic WH, Gordon AJ, Donohue JM, Gellad WF. Defining nonmedical use of prescription opioids within health care claims: a systematic review. Subst Abus. 2015;36:192–202.
  • Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. 2006;83(Suppl 1):S4–S7.
  • Barrett SP, Meisner JR, Stewart SH. What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Curr Drug Abuse Rev. 2008;1:255–262.
  • Kristman V, Manno M, Cote P. Loss to follow-up in cohort studies: how much is too much? Eur J Epidemiol. 2004;19:751–760.
  • Crowley DM, Jones DE, Coffman DL, Greenberg MT. Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial. Prev Med. 2014;62C:71–77.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.